Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody-远泰生物

提醒成功

QQ登录

微信登录

同意并阅读使用条款和隐私策略

账号密码登录

微信/QQ登录

没有账号？立即注册

搜索

抗体销售咨询健康评估咨询 mRNA-LNP咨询

0731-88388787

首页 > 产品中心 > 产品详情

产品规范
Type	In Vivo - Reseach Grade Antibody
Host	CHO cells
catalog#	B00046
Application	Flow cytometry, animal model study
Aliases	CC chemokine receptor type 4, CC-CKR-4, CD194, CKR4, CMKBR4, ChemR13, HGCN:14099, K5-5, C-C motif chemokine receptor 4
Size/Concentration	1mg/5mg/20mg
Isotype	Human IgG1 kappa
Storage	Store at 4°C 1 month, store at -20°C to -70°C 12 month. protected from prolonged exposure to light. Avoid freeze/thaw cycles.
Species Reactivity	Human
Immunogen	Human CCR4
Formulation	PBS, pH 7.4

Description
Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.

Description

Mogamulizumab Biosimilar uses the same protein sequences as the therapeutic antibody mogamulizumab. Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Mogamulizumab selectively binds to and inhibits the activity of CCR4, which may block CCR4-mediated signal transduction pathways and, so, chemokine-mediated cellular migration and proliferation of T cells, as well as chemokine-mediated angiogenesis. Additionally, this agent may induce antibody-dependent cell-mediated cytotoxicity (ADCC) against CCR4-positive T cells. CCR4, a G-coupled-protein receptor for C-C chemokines such MIP-1, RANTES, TARC and MCP-1, is expressed on the surfaces of some types of T cells, endothelial cells, and certain types of neurons. CCR4, also known as CD194, may be overexpressed on adult T-cell lymphoma (ATL) and peripheral T-cell lymphoma (PTCL) cells. In addition to directly targeting malignant T cells expressing CCR4, mogamulizumab depletes Treg cells, an important therapeutic target in many human cancers because of their role in suppressing host antitumor immunity.

Mogamulizumab Biosimilar, CCR4 Monoclonal Antibody B00046

规格：

1mg
5mg
20mg

数量：

说明书：

¥3250

~~¥3250~~

加入购物车

立即购买

咨询

ProMab Biotechnologies, Inc.

联系方式

CONTACT

联系电话:

0731-88388787
公司邮箱:

sales@promab.cn
公司地址:

湖南省长沙市高新开发区林语路239号顺畅产业园5楼
湖南省长沙市望城区普瑞大道8号出版科技园2号楼

官方微信

产品中心

Product

技术服务

service

客户留言

message